Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Black Diamond Therapeutics (BDTX) Liabilities and Shareholders Equity (2018 - 2025)

Black Diamond Therapeutics' Liabilities and Shareholders Equity history spans 6 years, with the latest figure at $143.0 million for Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity rose 16.61% year-over-year to $143.0 million; the TTM value through Dec 2025 reached $643.4 million, up 16.33%, while the annual FY2025 figure was $143.0 million, 16.61% up from the prior year.
  • Liabilities and Shareholders Equity reached $143.0 million in Q4 2025 per BDTX's latest filing, down from $157.7 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $313.3 million in Q1 2021 to a low of $122.6 million in Q4 2024.
  • Average Liabilities and Shareholders Equity over 3 years is $188.3 million, with a median of $157.7 million recorded in 2025.
  • Peak YoY movement for Liabilities and Shareholders Equity: dropped 20.87% in 2021, then grew 23.66% in 2025.
  • A 3-year view of Liabilities and Shareholders Equity shows it stood at $274.1 million in 2021, then crashed by 55.26% to $122.6 million in 2024, then grew by 16.61% to $143.0 million in 2025.
  • Per Business Quant, the three most recent readings for BDTX's Liabilities and Shareholders Equity are $143.0 million (Q4 2025), $157.7 million (Q3 2025), and $166.4 million (Q2 2025).